September 06, 2025 a 01:01 pm

ZBH: Fundamental Ratio Analysis - Zimmer Biomet Holdings, Inc.

ZBH stock analysis

Zimmer Biomet Holdings, Inc. has a strong presence in the musculoskeletal healthcare business, offering a diverse product range for orthopedic and dental solutions. The stock has been performing steadily with promising fundamentals that appeal to investors and analysts alike. With a focus on innovation, Zimmer Biomet continues to expand its market presence globally.

Fundamental Rating

Zimmer Biomet shows a moderate to strong financial performance across key metrics. Below are the ratings for fundamental financial categories:

Category Score Score Bar
Discounted Cash Flow 5
Return on Equity 4
Return on Assets 4
Debt to Equity 1
Price to Earnings 2
Price to Book 3

Historical Rating

The historical ratings indicate consistency over time, with stable scores in major categories:

Date Overall DCF ROE ROA Debt to Equity P/E P/B
2025-09-05 3 5 4 4 1 2 3
N/A 0 5 4 4 1 2 3

Analyst Price Targets

Zimmer Biomet shows promising price targets based on analyst forecasts:

High Low Median Consensus
$115 $96 $101 $104.4
Stock price chart for ZBH

Analyst Sentiment

The sentiment among analysts remains positive, predominantly favoring buy recommendations:

Recommendation Count Distribution
Buy 20
Hold 18
Sell 3

Conclusion

Zimmer Biomet Holdings, Inc. presents a stable investment with a reasonably strong financial backbone and favorable analyst ratings. Despite a challenging market environment, the company's consistent product innovation and strategic market expansion offer growth potential. Investors might find the stock appealing given its strong fundamentals and positive industry outlook. However, as with any investment, consideration of risks like regulatory changes and market volatility is essential. Overall, Zimmer Biomet warrants attention for those seeking exposure in the healthcare sector.